Valneva Reports Nine-Month 2021 Revenue and Cash
Strong financial position
Total revenue (excluding COVID) of €69.8 million in the first nine months of 2021 compared to €58.8 million in the first nine months of 2020
Updated 2021 financial guidance (excluding COVID)
Valneva confirms that Peter Bühler will join the Company as Chief Financial Officer on January 1, 2022 and has appointed Vincent Dequenne, formerly Senior Vice President Operations, as Chief Operating Officer.
Key Milestones Achieved in 2021 include:
Lyme Disease Vaccine Candidate VLA15
Inactivated COVID-19 Vaccine Candidate VLA2001
Single-Shot Chikungunya Vaccine Candidate VLA1553
Raised approximately $210 million
Thomas Lingelbach, Valneva’s Chief Executive Officer, commented, “Valneva is continuing to deliver on its R&D objectives. This year, we successfully advanced our clinical programs and reported positive Phase 3 results for two vaccine candidates. If approved, we expect both vaccines to make a positive change to people’s lives. Based on the strong tolerability and immunogenicity of our differentiated COVID-19 vaccine candidate, we have been able to get a deal approved by the EC and are grateful for the trust and confidence the EU has put in us and VLA2001. Our team has delivered phenomenally well this year and I would like to thank them for their continued commitment and dedication. I would also like to thank our long term shareholders for their support.”
Saint Herblain (France), November 18, 2021 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) a specialty vaccine company, today reported its revenue and cash balance for the first nine months of the year 2021.
About Valneva SE
Continental Breakfast - For Paid Conference Pass Holders, Exhibitors, Sponsors, Speakers, Press
Blockchain Keynote: Blockchain POV - Custody and Blockchain in Banking
Battle of the Sixes -- To the Victor goes the Spoils